Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $19.00.

ARTV has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Thursday, October 30th. HC Wainwright upped their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Wedbush raised their price objective on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Finally, Jefferies Financial Group raised Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th.

Insider Buying and Selling

In related news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $6.00, for a total value of $153,000.00. Following the sale, the chief executive officer owned 356,721 shares of the company’s stock, valued at $2,140,326. The trade was a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 35,062 shares of company stock valued at $193,670 over the last three months. 21.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Ground Swell Capital LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at $38,000. Y Intercept Hong Kong Ltd acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth about $48,000. Marshall Wace LLP bought a new stake in Artiva Biotherapeutics during the 2nd quarter worth about $79,000. Qube Research & Technologies Ltd acquired a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $58,000. Finally, Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $67,000.

Artiva Biotherapeutics Trading Up 6.1%

Shares of Artiva Biotherapeutics stock opened at $4.86 on Friday. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $10.18. The company’s fifty day simple moving average is $3.87 and its 200-day simple moving average is $3.24. The company has a market cap of $119.31 million, a price-to-earnings ratio of -1.88 and a beta of 2.92.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. As a group, research analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.